GlassScriptPhysician profile
Deanna Weaver
NPI 1821609074
$1,486.31
in general payments reported to CMS, 2019-2025
26 companies · $805 in 2025
The $805 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.62 · 2022: $231 · 2023: $260 · 2024: $178 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.25 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $151.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.18 | 2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $136.34 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $101.05 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $76.10 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $73.46 | 2022-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.98 | 2025 | Caplyta |
| Lilly USA, LLC | $67.89 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $62.46 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $51.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.04 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $42.19 | 2025 | Gemtesa |
| Radius Health, INC. | $30.29 | 2025 | Tymlos |
| Sage Therapeutics, LLC | $26.93 | 2025 | Zurzuvae |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.20 | 2025 | |
| Sanofi Pasteur INC. | $20.95 | 2023 | |
| Insulet Corporation | $18.71 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $17.77 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.81 | 2022 | |
| Amgen INC. | $15.04 | 2023 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $14.49 | 2023 | |
| Axsome Therapeutics, INC. | $14.04 | 2025 | Symbravo |
| Exact Sciences Corporation | $14.00 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $13.94 | 2023 | Intellis Adaptivestim |
| Currax Pharmaceuticals LLC | $13.31 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.